Wei Tang, Lin Qi, Minfeng Chen, Ye Zhang, Yongxiang Tang, Shuo Hu, Xiaomei Gao, Yi Cai
{"title":"[68Ga]Ga-RM26 PET/CT与[68Ga]Ga-PSMA-617 PET/CT在前列腺癌盆腔淋巴结转移检测中的附加价值:一项前瞻性、单中心、II期研究","authors":"Wei Tang, Lin Qi, Minfeng Chen, Ye Zhang, Yongxiang Tang, Shuo Hu, Xiaomei Gao, Yi Cai","doi":"10.2967/jnumed.124.269189","DOIUrl":null,"url":null,"abstract":"<p>Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [<sup>68</sup>Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT remains underexplored. <strong>Methods:</strong> This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. <strong>Results:</strong> In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined use of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined [<sup>68</sup>Ga]Ga-RM26 and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. <strong>Conclusion:</strong> In dual-target imaging, [<sup>68</sup>Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"49 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study\",\"authors\":\"Wei Tang, Lin Qi, Minfeng Chen, Ye Zhang, Yongxiang Tang, Shuo Hu, Xiaomei Gao, Yi Cai\",\"doi\":\"10.2967/jnumed.124.269189\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [<sup>68</sup>Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT remains underexplored. <strong>Methods:</strong> This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. <strong>Results:</strong> In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined use of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [<sup>68</sup>Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. [<sup>68</sup>Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT. The combined [<sup>68</sup>Ga]Ga-RM26 and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. <strong>Conclusion:</strong> In dual-target imaging, [<sup>68</sup>Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [<sup>68</sup>Ga]Ga-RM26 PET/CT and [<sup>68</sup>Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.</p>\",\"PeriodicalId\":22820,\"journal\":{\"name\":\"The Journal of Nuclear Medicine\",\"volume\":\"49 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.124.269189\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.124.269189","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study
Lymph node staging in prostate cancer is crucial for treatment and prognosis, yet [68Ga]Ga-PSMA-617 PET/CT has limited sensitivity in detecting pelvic lymph node metastasis (PLNM). [68Ga]Ga-RM26 PET/CT, targeting the gastrin-releasing peptide receptor, complements [68Ga]Ga-PSMA-617 PET/CT in assessing primary tumor extension and aggressiveness. However, its role in detecting PLNM and complementing [68Ga]Ga-PSMA-617 PET/CT remains underexplored. Methods: This prospective study enrolled newly diagnosed yet untreated prostate cancer patients who underwent [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT, followed by radical prostatectomy and extended pelvic lymph node dissection. The primary objective was to evaluate the diagnostic performance of both PET/CT modalities in detecting PLNM. Results: In total, 68 patients were enrolled, with a 30.9% (21/68) pathologic PLNM rate. In patient-based analysis, [68Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.43 and 0.94, respectively, compared with 0.52 and 0.89 for [68Ga]Ga-PSMA-617 PET/CT. [68Ga]Ga-RM26 PET/CT detected additional PLNMs in 50% (5/10) of patients that were missed by [68Ga]Ga-PSMA-617 PET/CT. The combined use of [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT resulted in sensitivity of 0.76 and specificity of 0.85. In total, 1,049 lymph nodes were dissected, including 991 normal and 58 positive nodes. In lesion-based analysis, [68Ga]Ga-RM26 PET/CT had sensitivity and specificity of 0.38 and 0.99, respectively, compared with 0.5 and 0.99 for [68Ga]Ga-PSMA-617 PET/CT. [68Ga]Ga-RM26 PET/CT identified 41.4% (12/29) of pathologic positive nodes missed by [68Ga]Ga-PSMA-617 PET/CT. The combined [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT demonstrated sensitivity of 0.71 and specificity of 0.99. Conclusion: In dual-target imaging, [68Ga]Ga-RM26 PET/CT identified additional PLNMs. The combination of [68Ga]Ga-RM26 PET/CT and [68Ga]Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity with minimal loss of specificity.